Presentation is loading. Please wait.

Presentation is loading. Please wait.

Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation  Takashi Tanaka, Yoshihiro Inamoto, Takuya Yamashita,

Published byOliver King Modified over 5 years ago

Similar presentations

Presentation on theme: "Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation  Takashi Tanaka, Yoshihiro Inamoto, Takuya Yamashita,"— Presentation transcript:

1 Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation 
Takashi Tanaka, Yoshihiro Inamoto, Takuya Yamashita, Shigeo Fuji, Keiji Okinaka, Saiko Kurosawa, Sung-Won Kim, Ryuji Tanosaki, Takahiro Fukuda  Biology of Blood and Marrow Transplantation  Volume 22, Issue 5, Pages (May 2016) DOI: /j.bbmt Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 The cumulative incidence of platelet recovery to ≥50,000/μL without transfusion. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 The cumulative incidence of platelet recovery to ≥50,000/μL without transfusion. Results are stratified according to (A) prolonged isolated thrombocytopenia (PIT) versus secondary failure of platelet recovery (SFPR), and (B) normal versus decreased numbers of megakaryocytes before starting eltrombopag. P values were derived from the Grey test. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation  Takashi Tanaka, Yoshihiro Inamoto, Takuya Yamashita,"

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.

Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Disease  Yayoi Matsumura-Kimoto, Yoshihiro.

Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Disease  Yayoi Matsumura-Kimoto, Yoshihiro.
Vaccination of Children following Allogeneic Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.
Hematologic Safety Profile of Linezolid in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation  Nina Cohen, Coralia N. Mihu, Susan.

Hematologic Safety Profile of Linezolid in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation  Nina Cohen, Coralia N. Mihu, Susan.
Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients  Bernard Lawrence Marini, Sung Won Choi, Craig Alan Byersdorfer, Simon.

Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients  Bernard Lawrence Marini, Sung Won Choi, Craig Alan Byersdorfer, Simon.
Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation  Kazuko.

Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation  Kazuko.
World Marrow Donor Association Crisis Response, Business Continuity, and Disaster Recovery Guidelines  Julia Pingel, Cullen Case, Beth Amer, Raymond A.

World Marrow Donor Association Crisis Response, Business Continuity, and Disaster Recovery Guidelines  Julia Pingel, Cullen Case, Beth Amer, Raymond A.
NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.

NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia  Hawk Kim, Kyoo-Hyung Lee, Sung-Soo Yoon, Sang.

Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia  Hawk Kim, Kyoo-Hyung Lee, Sung-Soo Yoon, Sang.
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Similar presentations

Ads by Google